top of page

Publications

Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder

J Am Pharm Assoc. DOI: 10.1016/j.japh.2023.06.010.

Zalmai RS, Hill LG, Loera LJ, Mosgrove Q, Brown CM.

Read More

Medications for opioid use disorder in professional recovery programs in the U.S.: Policies and recommendation patterns

Ment Health Clin. DOI: 10.9740/mhc.2023.06.163.

Murchison ML, Loera LJ, Hill LG.

Read More

Research and scholarly methods: Audit studies

J Am Coll Clin Pharm. DOI: 10.1002/jac5.1782

Loera LJ, Hill LG, Evoy KE, Reveles KR.

Read More

A wound care and immunization needs assessment for participants of a mobile syringe services program in Austin, Texas.

J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.018

Britton TR, Clague MR, Zagorski CM, Hill LG, Loera LJ.

Read More

A qualitative exploration of unintentional vs. intentional exposure to fentanyl among people who use drugs in Austin, Texas.

J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.10.005

Cance JD, Bingaman A, Kane H, Hairgrove S, Torrez SB, Buck A, Zagorski CM, Loera LJ, Hill LG.

Read More

Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice

Subst Abus. 2022. DOI: 10.1080/08897077.2022.2060423.

Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG.

Read More

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Drug Alcohol Depend. 2022. DOI: 0.1016/j.drugalcdep.2022.109518.

Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky VS, Yeung MS, Zagorski CM, Reveles KR.

Read More

Description and Evaluation of a Pilot Advanced Pharmacy Practice Experience in Addiction Medicine

Am J Pharm Educ. 2022. DOI: 10.5688/ajpe8926

Loera LJ, Hill LG, Zagorski CM, Jermain ML, Tirado CF.

Read More

Increasingly powerful opioid antagonists are not necessary

Int J Drug Policy. 2022. DOI: 10.1016/j.drugpo.2021.103457.

Hill LG, Zagorski CM, Loera LJ.

Read More

Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.

Subst Abus. 2022. DOI: 10.1080/08897077.2021.2010161

White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.

Read More
bottom of page